SUPPORT HEFFTER
SUBSCRIBE TO RSS
Recent News:
Can psychedelic trips cure PTSD and other maladies? | Washington Post
Psilocybin, Addiction, and End of Life--Stephen Ross
UNM alcohol dependence study--Sarah's story
Recovery: an alcoholic's story and the reemergence of psychedelic medicine | TEDxABQ
German documentary about psilocybin features Heffter board member
Psilocybin, where science meets spirituality | CBS News
Newsweek article covers psychedelic research
Experiences of hallucinogen treatment | The Psychologist
Heffter researcher Roland Griffiths on psilocybin and mysticism | TEDx
Magic Mushrooms Help Smokers Kick Habit in Small Study | Bloomberg

Can psychedelic trips cure PTSD and other maladies? | Washington Post

divider

The Washington Post is featuring an article by Tom Shroder adapted from his book Acid Test: LSD, Ecstasy, and the Power to Heal (Blue Rider Press, 2014). Shroder covers the history of psychedelic research from Albert Hoffman’s discovery of LSD in the 1940s to recent work by Heffter researcher Matthew Johnson on the use of psilocybin to treat tobacco addiction. Among other milestones, Shroder notes that some researchers credit the beginning of modern brain science to the discovery that the LSD molecule and the neurotransmitter serotonin are remarkably similar.

“After more than 30 years in which psychedelics were considered dangerous remnants of the 1960s, the drugs have begun to make a comeback, this time as potential remedies for a host of tough-to-treat maladies. Pilot studies and clinical trials of LSD, psilocybin, ketamine and MDMA have shown that the drugs, often in combination with talk therapy, can be given safely under medical supervision and may help people dealing with opiate and tobacco addiction, alcoholism, anxiety, depression, and post-traumatic streass disorder, or PTSD.”

 Can psychedelic trips cure PTSD and other maladies? | Washington Post


Psilocybin, Addiction, and End of Life–Stephen Ross

divider

In this presentation from the 2013 Psychedelic Science conference, Heffter researcher Stephen Ross discusses the use of psilocybin to treat addiction and psychological distress in cancer patients.

Psilocybin, Addiction, and End of Life–Stephen Ross


UNM alcohol dependence study–Sarah’s story

divider

Our video page features a new interview from the research study on psilocybin as a treatment for alcohol dependence conducted by Heffter researcher Michael Bogunschutz and his team at the University of New Mexico. Sarah, the volunteer subject interviewed in the video, is an alcoholic who received psilocybin during two treatment sessions. She speaks of the “journey of love” she experienced and the profound changes that have occurred in her life as a result of her participation in the study. The UNM study is the first time that psychedelics have been used as a treatment for alcohol dependence in about 50 years.

Heffter research videos


Recovery: an alcoholic’s story and the reemergence of psychedelic medicine | TEDxABQ

divider

In this TEDxABQ talk, research scientist Robert Rhatigan discusses his recovery from alcoholism using the psychedelic ayahuasca. In addition to his personal story, Rhatigan gives a brief history of psychedelic research including the work of Heffter researcher Michael Bogenschutz, who studied the treatment of alcoholics using psilocybin.

Recovery: an alcoholic’s story and the reemergence of psychedelic medicine | TEDxABQ


German documentary about psilocybin features Heffter board member

divider

For those of you who can speak German, here is a short clip from a film about Psilocybin as medicine featuring Heffter Board Member Dr. Franz Vollenweider.

Sie wirken ähnlich wie die Droge LSD auf das Gehirn: Magic mushrooms verändern die Wahrnehmung, machen euphorisch und können Halluzinationen erzeugen. Hervorgerufen werden sie vom psychoaktiven Wirkstoff Psilocybin, der in diesen Pilzen steckt. Die Hippie-Szene machte sich diesen Stoff zu eigen und etablierte ihn bis in die 1970er-Jahre als Modedroge. Die Folge: Psilocybin geriet in Verruf, die Forschung am Wirkstoff ins Stocken. Dabei hat Psilocybin möglicherweise das Potenzial zum Heilmittel und könnte eine Renaissance erfahren.

Dorge oder Medizin:”Magic Mushrooms” im Fokus der Wissenschaft

 


Psilocybin, where science meets spirituality | CBS News

divider

A CBS News program on addiction features Heffter researcher Stephen Ross and his upcoming study on the use of psilocybin to treat alcoholism. The interview, which is part of the #14Days on the Wagon series on CBS, focuses on the spiritual dimension of addiction.

“Ross believes using psilocybin medically in a controlled setting along with motivational interviewing can induce a spiritual experience that can bring an addict back from the brink of despair and give him hope and motivation to recover.

“Ross says, ‘By inducing a spiritual awakening, it may shift the person who’s addicted from this path they’re on which is very dark and going toward destruction… towards a different path and a connection back into their lives and developmental tracks.’”

#14Days: Psilocybin, where science meets spirituality | CBS News


Newsweek article covers psychedelic research

divider

An article in Newsweek magazine reports on speakers and topics from the recent Horizons conference in New York City. In “Ecstasy and Acid in Your Medicine Cabinet? Doctors Explore Psychedelics,” published on October 14th, 2014, writer Douglas Main provides an overview of past and current psychedelic research. The article mentions several studies on psilocybin by Heffter researchers.

“Psilocybin, the active ingredient in so-called ‘magic mushrooms,’ has been shown to reduce anxiety and depression in several small studies, including one 2010 study at UCLA published in Archives of General Psychiatry and another in progress at Johns Hopkins. A paper that came out this spring done by researchers from the Psychiatric University Hospital of Zurich published in the journal Biological Psychiatry found that psilocybin decreases activity in the amygdala, the part of the brain that may be overactive in people with anxiety and depression.”

Ecstasy and Acid in Your Medicine Cabinet? Doctors Explore Psychedelics | Newsweek


Experiences of hallucinogen treatment | The Psychologist

divider

An article in The Psychologist, the official publication of the British Psychological Society, covers recent work on the use of psilocybin to treat emotional distress in cancer patients. “Experiences of hallucinogen treatment”–published in the magazine’s September, 2014 issue–focuses on studies by Heffter researchers Charles Grob and Roland Griffiths. Their results indicate that psilocybin shows great promise as a treatment for the psychological problems that often accompany advanced stage cancer.

“The recent studies affirm that therapy with psilocybin is well tolerated and for some patients remarkably effective. It entails just one or two sessions and correspondingly low cost. Psilocybin has no known tissue toxicity. The reported incidences of adverse reactions, such as severe disorientation, anxiety and panic, are very low; and such side-effects can be managed using familiar doses of anxiolytics and neuroleptics. The experiences patients describe are not intoxication, but rather a sense of clarity, expanded context and a reframing of their worldview and sense of the future that persists long after any pharmacologic effect of the drugs.”

Experiences of hallucinogen treatment | The Psychologist


Heffter researcher Roland Griffiths on psilocybin and mysticism | TEDx

divider

In this TEDx talk, Heffter board member Roland Griffiths speaks about his research on psilocybin and the mystical experience. Griffiths and his team at Johns Hopkins recruited 36 individuals with experience in spiritual or religious activities but no prior use of psychedelics. Although the primary goal of the study was to assess the effects of large doses of psilocybin, the study participants reported profound mystical experiences. Seventy percent of the participants reported that the psilocybin experience was among the top five most important events in their lives. According to Griffiths,”Psilocybin looks identical to naturally occurring religious experience.”

Heffter researcher Roland Griffiths on psilocybin and mysticism | TEDx


Magic Mushrooms Help Smokers Kick Habit in Small Study | Bloomberg

divider

Heffter researcher Matt Johnson and his colleagues at Johns Hopkins University have completed a study showing that psilocybin (aka “magic mushrooms”) is a useful treatment for heavy smokers who want to quit. According to Bloomberg.com writer Michelle Fay Cortez:

Just two or three experiences with the hallucinogenic drug known as magic mushrooms helped a dozen long-term smokers quit, succeeding in a study where numerous other approaches failed.

The volunteers took a pill containing psilocybin, the active ingredient in magic mushrooms, as part of a cognitive behavior therapy program at Johns Hopkins University in Baltimore. Six months later, 12 of the 15 participants remained smoke-free, according to the study results published today in the Journal of Psychopharmacology.

Magic Mushrooms Help Smokers Kick Habit in Small Study | Bloomberg.com

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction | Journal of Psychopharmacology